Company: INTS
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001567264-25-000103
Chunk: 22

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
72,667)$2,184  Stock-based compensation expense -- 471 - 471  Issuance of common stock in ATM offering, net of $301 issuance costs 22,902,1982 7,236 - 7,238  Net loss -- - (2,671)(2,671) Balances at September 30, 202549,068,621$5 $82,555 $(75,338)$7,222 

Common StockAdditional Paid in CapitalAccumulated DeficitStockholders’ EquitySharesAmount Balances at December 31, 202313,709,377$1 $63,676 $(50,515)$13,162  Exercise of warrants2,500- 8 - 8  Stock-based compensation expense -- 1,155 - 1,155  Net loss -- - (4,603)(4,603) Balances at March 31, 202413,711,877$1 $64,839 $(55,118)$9,722  Exercise of options1,000- 3 - 3  Stock-based compensation expense -- 591 - 591  Net loss -- - (4,971)(4,971) Balances at June 30, 202413,712,877$1 $65,433 $(60,089)$5,345  Exercise of options 87,500- 263 - 263  Stock-based compensation expense -- 483 - 483  Issuance of common stock in exchange for services 11,750- 51 - 51  Issuance of common stock in ATM offering, net of $82 issuance costs 51,820- 150 - 150  Net loss -- - (3,513)(3,513) Balances at September 30, 202413,863,947$1 $66,380 $(63,602)$2,779 

The accompanying notes are an integral part of these condensed financial statements.

3

INTENSITY THERAPEUTICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

Nine Months Ended September 30,20252024Cash flows from operating activities:Net loss$(8,555)$(13,087)